Results 291 to 300 of about 20,489,060 (330)
Some of the next articles are maybe not open access.

Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism.

Current drug metabolism, 2019
BACKGROUND Recent US Food and Drug Administration (FDA) draft guidance on pharmacokinetic drugdrug interactions (DDIs) has highlighted the clinical importance of ABC transporters B1 or P-glycoprotein (P-gp), hepatic organic anion-transporting polypeptide
Y. Akamine, N. Yasui-Furukori, T. Uno
semanticscholar   +1 more source

A porcine lymphocyte model for P‐gp inhibition studies

Journal of Veterinary Pharmacology and Therapeutics, 2011
Short ...
Schrickx, J.A., Fink-Gremmels, J.
openaire   +2 more sources

A plausible explanation for enhanced bioavailability of P-gp substrates in presence of piperine: simulation for next generation of P-gp inhibitors

Journal of Molecular Modeling, 2012
P-glycoprotein (P-gp) has a major role to play in drug pharmacokinetics and pharmacodynamics, since it effluxes many cytotoxic hydrophobic anticancer drugs from gastrointestinal tract, brain, liver and kidney. Piperine is known to enhance the bioavailability of curcumin, as a substrate of P-gp by at least 2000%.
Durg Vijay, Singh   +2 more
openaire   +2 more sources

P-glycoprotein (P-gp/MDR1)-Mediated Efflux of Sex-Steroid Hormones and Modulation of P-gp Expression In Vitro

Pharmaceutical Research, 2004
To determine whether female sex-steroid hormones and their metabolites can modulate P-glycoprotein (P-gp) expression and catalytic activity and to investigate P-gp mediated transport of these sex-steroids across MDR1-transfected Madine-Darby canine kidney (MDCK) cells.Changes in P-gp protein and MDR1 mRNA expression levels were examined in the presence
Winnie Y, Kim, Leslie Z, Benet
openaire   +2 more sources

Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions

Pharmaceutical Research, 2023
The differences between intestinal and systemic (hepatic and renal) P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) roles in drug disposition are difficult to define. Accordingly, we characterized Encequidar (ECD) as an intestinal P-gp and BCRP specific inhibitor to evaluate their role in drug disposition.We assessed the in vitro and ...
Jessica Chu   +12 more
openaire   +2 more sources

P-gp Transporter and its Role in Neurodegenerative Diseases

Current Topics in Medicinal Chemistry, 2009
This paper describes an overview of recent insights concerning some socially relevant neurodegenerative diseases such as Alzheimer's (AD), Parkinson's (PD), Huntington's (HD) and Creutzfeldt-Jakob's (CJD) diseases, amyotrophic lateral sclerosis (ALS) and epilepsy.
RAPPOSELLI, SIMONA   +2 more
openaire   +2 more sources

Importance of P-gp PET Imaging in Pharmacology

Current Pharmaceutical Design, 2016
Capillary endothelial cells in the brain express P-glycoprotein (P-gp), which works as a functional blood-brain barrier (BBB). P-gp pumps out multiple types of molecules from the brain parenchyma into the blood. Therefore, altered P-gp function at the BBB will change the concentrations of therapeutic drugs in the central nervous system (CNS) and hence ...
openaire   +2 more sources

A New Method to Measure P-gp (ABCB1) Activity

Drug Metabolism Letters, 2007
We have developed an easy and sensitive method to measure P-glycoprotein (P-gp) activity using [gamma-(32)P]ATP and charcoal. This method utilizes the nature of adsorption of organic phosphate to charcoal. The standard assay method is as follows: the reaction mixture (20 microl) of 1 mM [gamma-(32)P]ATP (1 Ci/mol), 2.5 microg P-gp membranes, and the ...
Masatoshi, Masuda, Takaharu, Mizutani
openaire   +2 more sources

Discovery of traditional Chinese medicine monomers and their synthetic intermediates, analogs or derivatives for battling P-gp-mediated multi-drug resistance.

European journal of medicinal chemistry, 2018
P-glycoprotein (P-gp)-mediated multi-drug resistance (MDR) is a well-documented and predominant phenotype hampering patients' response to cancer chemotherapy.
Xiaodong Ma   +3 more
semanticscholar   +1 more source

Effect of berberine on the pharmacokinetics of substrates of CYP3A and P‐gp

Phytotherapy Research, 2009
AbstractThein vivoeffects of berberine (BBR), the widely used bioactive herbal ingredient from many traditional Chinese medicinal herbs, on the pharmacokinetics of carbamazepine (CBZ, a substrate of CYP3A) and its metabolite carbamazepine 10,11‐epoxide (ECBZ), digoxin (DIG, a substrate of P‐gp) and cyclosporine A (CsA, a dual substrate of CYP3A and P ...
W, Qiu   +4 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy